Tirzepatide 5 vials of 10mg each 50mg kit ZPHC
  • Out-of-Stock
Tirzepatide 5 vials of 10mg each 50mg kit ZPHC

Tirzepatide 5 vials of 10mg each 50mg kit ZPHC

$0.00

Volume discounts

QuantityUnit discountYou Save
3$40.00$120.00
6$80.00$480.00

Out-of-Stock
Add to Wishlist
SKU: Tirzepatide 5 vials of 10mg each 50mg kit ZPHC
Description

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety.

Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing.

Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. Later, it was approved under a different brand name ZEPBOUND on November 8, 2023, for the chronic weight management in adults with obesity or overweight with at least one weight-related condition. On September 15, 2022, tirzepatide was also approved by the European Commission.

Product Details
ZPHC
Tirzepatide 5 vials of 10mg each 50mg kit ZPHC
Reviews(0)

Reviews

No customer reviews for the moment.

You're reviewing “Tirzepatide 5 vials of 10mg each 50mg kit ZPHC”


.png .jpg .gif

Featured products

This website use cookies to ensure you get the best experience on our website.Privacy Policy

Sign in

Megamenu

Your cart

There are no more items in your cart